Research at Oslo University Hospital

The session will take place on 10 June 2026, from 13:00 to 14:00, and will be led by Dr Kelly Kohut.

By bringing patient experiences into the discussion, the session will provide valuable insights into how care, communication and clinical approaches can better respond to the needs of individuals and families affected by Lynch syndrome.

Chloé B. Steen, leader of the Cancer Biology in Silico project group at the Department of Medical Genetics at OUS and UiO, has been awarded the Anders Jahre Medical Prize for Young Researchers 2026.
Steen has developed advanced bioinformatic tools to characterise cells in tissues. Importantly, these tools have deepened our understanding of how cellular composition can influence cancer.
The Anders Jahre Medical Prize is one of the largest prizes in biomedical research in the Nordic region. Each year, a main prize and a prize for young medical researchers are awarded. This year, the prizes will be awarded in November. Steen shares the prize for young researcher with Heidi Haikala of the University of Helsinki. 

The prestigious interdisciplinary prize from the European Society for Radiotherapy and Oncology (ESTRO) honors outstanding research and significant contributions across disciplines within radiation oncology. The award highlights both the high quality of the research environment and the importance of interdisciplinary collaboration in the development of future cancer treatments.
This year, the prize was given to Heidi Lyng, head of the Clinical Radiation Biology group at the Institute for Cancer Research, for her work to understand the radiobiology of patient tumors and translate this knowledge into clinical practice.

During this year's annual innovation celebration, Inven2 brought forward researchers and innovations that demonstrate how research from the University of Oslo and Oslo University Hospital can be developed into solutions with significant value for patients, business and society. Three awards were presented during the celebration: the Innovation Award 2026, the Innovator of the Year and the Audience Award.
The Innovator of the Year 2026 award went to Professor Guro Elisabeth Lind, head of the Epigenetics Group at the Department of Molecular Oncology at the Institute for Cancer Research, Oslo University Hospital.

Each year, the University of Oslo (UiO) honors outstanding achievements when the University Board presents awards for research, education, dissemination and innovation.
This year, Anne Simonsen will be awarded the Research Prize for her groundbreaking studies of autophagy. Through her research, Simonsen has played a key role in demonstrating that reduced autophagy is an important factor in ageing, as well as in neurodegenerative diseases and cancer. We congratulate Anne Simonsen on this well-deserved recognition. She will receive the Research Prize during UiO’s Annual Celebration in September.

Recommended sites for current OUS research news:

From Oslo University Hospital, in Norwegian:
OUS Innsikt – ny forskning, innovasjon og behandling - channel for science communication
More news from OUS (oslo-universitetssykehus.no)

From UiO and centres of excellence (UiO/OUS):
News from the Inst. of Clinical Medicine, UiO
Research news - UiO
CanCell - Centre for Cancer Cell Reprogramming 
Cresco - Centre for Embryology and Healthy Development 
PRIMA - Precision Immunotherapy Alliance - Norwegian version
Hybrid Technology Hub - Centre for Organ on a Chip-Technology

King Olav V's Cancer Research Prize has been awarded every year since 1992 by the Norwegian Cancer Socitey to a cancer researcher or a research group that has contributed to promoting the quality and scope of Norwegian cancer research. The prize, amounting to 1 million NOK, has high prestige in the Norwegian research community and goes to the very best researchers within the entire spectrum of Norwegian cancer research.
For 2026, the award went to Johanna Olweus, leader of the the Experimental Immunotherapy Group at the Institute for Cancer Research. H.M. King Harald presented the prize during a ceremony in The Aula of the University of Oslo on May 19th.

The UiO Growth House help researchers to mature early-stage ideas. The University of Oslo has in 2026 allocated NOK 5 million for early-stage innovation projects in two categories.
Lorena Arranz, Leader of the Stem Cells, Ageing and Cancer group and Deputy Director of SFF CRESCO, has received NOK 400 000 for the test and further development phase of a succinate analogue suitable for therapeutic applications in cancer.
Sonja Hjellegjerde Brunvoll, Researcher in the Genome and Epigenome Regulation in Embryo Development, Ageing and Disease group, has received NOK 50 000 for her project ONCOFAST; Intermittent fasting during chemotherapy – a randomized feasibility study.

A team of researchers led by Jorrit Enserink from Oslo University Hospital and Helene Knævelsrud from the University of Oslo has been awarded 40 million NOK from the Research Council of Norway to investigate a fundamental biological question: Can cells remember being starved, and does that memory change how they behave in the future?

The project, called Total Recall (Learn–Recall–Forget: Causal Circuits of Starvation Memory for Population Coherence in Homeostasis and Development), was funded through the prestigious "Toppforskere" programme, which supports research teams with the potential to become world-leading in their field.